While vaccine and drug development have largely dominated the HIV field since the epidemic emerged, the past several years have brought about the burgeoning field of HIV cure. VIDD faculty are developing innovative approaches such as genome editing and genetically modified T cells to eradicate the latent viral reservoir in HIV+ individuals. Preclinical models of HIV infection are central to performing these immunotherapy experiments and have already begun to show great success.
Select a letter to display a list of Faculty members
Co-infections impact clinical, virological, and immunologic outcomes in HIV. I work on understanding how we can better treat patients to prevent HIV and HIV-associated complications, including focus on HIV persistence and HIV-associated malignancies.
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Developing methods and tools for high-throughput, high-dimensional experiments with applications in vaccine research, immunology and immunotherapy; flow cytometry, peptide microarrays, next generation sequencing; Bayesian inference and computation and statistical computing
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication startegies, and to use models to capture kinetic features of the human microbiome.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.